Signos has launched the first FDA-cleared, over-the-counter glucose monitoring system for weight management. By combining Dexcom’s Stelo biosensor with an AI-powered platform, the system gives users real-time feedback on how meals, exercise, sleep, and stress affect their metabolism. The goal is to provide personalized, accessible insights that help people manage their weight and overall health without the barriers of prescriptions or high costs.
Positioned as more than a product, Signos frames the system as part of a broader mission to tackle obesity and metabolic disease. With nearly three-quarters of U.S. adults overweight or obese, the company hopes its platform will empower individuals to make meaningful lifestyle changes and take control of their long-term health.